Is Liraglutide safe?
Well-StudiedSide effects, risks, and safety considerations based on available research.
Research status
Liraglutide has a relatively strong evidence base including clinical trials in humans. This does not mean it is without risks, but its safety profile is better characterized than many other peptides.
Known concerns & side effects
- ⚠GI side effects (nausea, vomiting, diarrhea) affect the majority of users early in treatment
- ⚠weight regain upon discontinuation — consistent with all GLP-1 class therapies
- ⚠FDA boxed warning: C-cell thyroid tumors in rodents; contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
- ⚠pancreatitis risk: rare but established
- ⚠requires daily injection — compliance burden vs once-weekly alternatives
- ⚠significantly less effective for weight loss than semaglutide or tirzepatide
Use caution with
Relevant safety research
LEADER: Liraglutide and cardiovascular outcomes in type 2 diabetes
Finding: MACE (major adverse cardiovascular events) reduced by 13% (HR 0.87, p=0.01); cardiovascular mortality reduced by 22% vs placebo over median 3.8 years.
Limitation: High-risk T2D population with established or high-risk cardiovascular disease; cardiovascular benefits may not generalize to patients using liraglutide solely for weight management.
See all 2 studies on the full Liraglutide profile.
Frequently asked questions
Why is liraglutide being replaced by semaglutide in practice?
The SUSTAIN-7 head-to-head trial showed semaglutide 1mg once weekly produces significantly more weight loss (4.6% more) and HbA1c reduction than liraglutide 1.2mg once daily. Combined with the convenience of once-weekly vs once-daily injection, semaglutide has become the preferred GLP-1 therapy for most patients. At obesity doses (2.4mg weekly semaglutide vs 3mg daily liraglutide), the gap is even larger.
What is the difference between Victoza and Saxenda?
Both contain liraglutide as the active ingredient. Victoza is approved for type 2 diabetes management, dosed up to 1.8mg/day. Saxenda is approved for chronic weight management in adults with BMI ≥30 (or ≥27 with weight-related comorbidity), dosed up to 3mg/day. The higher dose of Saxenda drives greater appetite suppression and weight loss compared to diabetes dosing.
Full Liraglutide Profile
Evidence, timeline, products & more
Take the Peptide Quiz
Get personalized recommendations
Last updated: 2026-06-10
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.